Global Myasthenia Gravis Market, Analysis and Forecast: 2025-2035
The global myasthenia gravis market is experiencing notable growth, driven by advancements in treatment options, increased awareness of autoimmune diseases, and rising demand for effective therapies across healthcare sectors. The development of novel biologics, immunosuppressive treatments, and surgical interventions is significantly contributing to the evolving landscape of the global myasthenia gravis market.
The introduction of monoclonal antibodies, as well as improved drug formulations and delivery methods, are key factors driving the growth of the global myasthenia gravis market. Additionally, the increasing use of plasmapheresis and intravenous immunoglobulin (IVIg) treatments, along with ongoing clinical research, is expected to continue shaping the market dynamics. Rising healthcare expenditure in developed regions like the U.S., Europe, and Japan, along with growing investments in healthcare infrastructure in emerging economies, further support the expansion of the global myasthenia gravis market.
An aging global population, particularly in developed markets, is another crucial driver for the growth of the global myasthenia gravis market. The higher prevalence of autoimmune diseases and associated disorders, including Myasthenia Gravis, in the elderly population is increasing the demand for early and accurate diagnosis, as well as effective disease management options. Moreover, ongoing advancements in diagnostic tools, such as antibody tests and electromyography (EMG), are improving detection and enabling more personalized treatment approaches, thereby expanding the scope of the market.
Despite these promising advancements, the global myasthenia gravis market faces challenges, including the high cost of treatment options and limited availability of therapies in low-income regions. These factors may hinder the accessibility and adoption of treatment methods, particularly in resource-constrained settings. However, continued research and development efforts by leading pharmaceutical companies, coupled with expanding insurance coverage and healthcare policies, are expected to address these barriers over time and fuel further market growth.
The competitive landscape of the global myasthenia gravis market is highly dynamic, with key players such as Argenx SE, UCB Pharma, Johnson & Johnson, and AstraZeneca actively engaging in strategic partnerships, mergers, and technological innovations. Continuous investments in the development of new biologic treatments and immunotherapy options are expected to intensify competition and drive market growth. These companies are focusing on expanding their product portfolios, improving therapeutic efficacy, and enhancing patient outcomes, which will contribute to the ongoing evolution of the global myasthenia gravis market.
The global myasthenia gravis market is projected to maintain a strong compound annual growth rate (CAGR) as advancements in treatment options align with rising clinical demand. The development of novel therapies and increased awareness about autoimmune diseases will collectively drive market growth. The global myasthenia gravis market is thus poised to play a critical role in the future of autoimmune disease management, improving patient outcomes and significantly contributing to healthcare delivery globally.
Market Segmentation:
Segmentation 1: by Drug Type
Cholinesterase Inhibitors
Monoclonal Antibodies
Corticosteroids
Others
Segmentation 2: by Region
North America
Europe
Asia-Pacific
Rest-of-the-World
The global myasthenia gravis market is expected to grow steadily, driven by continuous innovations in treatment options and improved therapeutic capabilities. Increasing investments in healthcare infrastructure across the U.S., Europe, and emerging markets will significantly influence market expansion. Advanced applications of biologic therapies and improved diagnostic tools for early disease detection are set to position the global myasthenia gravis market as a critical component in modern autoimmune disease management.
*PDF email from publisher allows for 1-3 users, with permission to print*
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- Executive Summary
- Scope and Definition
- Market/Product Definition
- Key Questions Answered
- Analysis and Forecast Note
- 1. Markets: Industry Outlook
- 1.1 Trends: Current and Future Impact Assessment
- 1.2 Epidemiological Analysis
- 1.3 Regulatory Landscape
- 1.4 Pipeline Analysis
- 1.5 Pricing Analysis
- 1.6 Market Dynamics Overview
- 1.6.1 Market Drivers
- 1.6.2 Market Restraints
- 1.6.3 Market Opportunities
- 2. Global Myasthenia Gravis Market (by Drug Class), ($Million) 2024-2035
- 2.1 Cholinesterase Inhibitors
- 2.2 Monoclonal Antibodies
- 2.3 Corticosteroids
- 2.4 Others
- 3. Global Myasthenia Gravis Market (by Region), ($Million) 2024-2035
- 3.1 North America
- 3.1.1 Market Dynamics
- 3.1.2 Market Sizing and Forecast
- 3.1.2.1 North America Myasthenia Gravis Market (by Country)
- 3.1.2.1.1 U.S.
- 3.1.2.1.2 Canada
- 3.2 Europe
- 3.2.1 Market Dynamics
- 3.2.2 Market Sizing and Forecast
- 3.2.2.1 Europe Myasthenia Gravis Market (by Country)
- 3.2.2.1.1 Germany
- 3.2.2.1.2 France
- 3.2.2.1.3 U.K.
- 3.2.2.1.4 Spain
- 3.2.2.1.5 Italy
- 3.2.2.1.6 Rest-of-Europe
- 3.3 Asia-Pacific Myasthenia Gravis Market
- 3.3.1 Market Dynamics
- 3.3.2 Market Sizing and Forecast
- 3.3.2.1 Asia-Pacific Myasthenia Gravis Market (by Country)
- 3.3.2.1.1 China
- 3.3.2.1.2 Japan
- 3.3.2.1.3 India
- 3.3.2.1.4 Australia
- 3.3.2.1.5 Rest-of-Asia-Pacific
- 3.4 Rest-of-the-World Myasthenia Gravis Market
- 3.4.1 Market Dynamics
- 3.4.2 Market Sizing and Forecast
- 3.4.2.1 Rest-of-the-World Myasthenia Gravis Market (by Country)
- 3.4.2.1.1 Brazil
- 3.4.2.1.2 U.A.E.
- 3.4.2.1.3 Rest of Rest-of-the-World
- 4. Myasthenia Gravis Market - Competitive Benchmarking & Company Profiles
- 4.1 Key Strategies and Development
- 4.1.1 Mergers and Acquisitions
- 4.1.2 Partnership, Alliances and Business Expansion
- 4.1.3 New Offerings
- 4.1.4 Regulatory Activities
- 4.1.5 Funding Activities
- 4.2 Company Profiles
- 4.2.1 Argenx SE
- 4.2.1.1 Overview
- 4.2.1.2 Top Products/Product Portfolio
- 4.2.1.3 Top Competitors
- 4.2.1.4 Target Customers
- 4.2.1.5 Key Personnel
- 4.2.1.6 Analyst View
- 4.2.2 UCB Pharma
- 4.2.2.1 Overview
- 4.2.2.2 Top Products/Product Portfolio
- 4.2.2.3 Top Competitors
- 4.2.2.4 Target Customers
- 4.2.2.5 Key Personnel
- 4.2.2.6 Analyst View
- 4.2.3 Johnson & Johnson
- 4.2.3.1 Overview
- 4.2.3.2 Top Products/Product Portfolio
- 4.2.3.3 Top Competitors
- 4.2.3.4 Target Customers
- 4.2.3.5 Key Personnel
- 4.2.3.6 Analyst View
- 4.2.4 AstraZeneca
- 4.2.4.1 Overview
- 4.2.4.2 Top Products/Product Portfolio
- 4.2.4.3 Top Competitors
- 4.2.4.4 Target Customers
- 4.2.4.5 Key Personnel
- 4.2.4.6 Analyst View
- 4.2.5 Novartis AG
- 4.2.5.1 Overview
- 4.2.5.2 Top Products/Product Portfolio
- 4.2.5.3 Top Competitors
- 4.2.5.4 Target Customers
- 4.2.5.5 Key Personnel
- 4.2.5.6 Analyst View
- 4.2.6 Roivant Sciences
- 4.2.6.1 Overview
- 4.2.6.2 Top Products/Product Portfolio
- 4.2.6.3 Top Competitors
- 4.2.6.4 Target Customers
- 4.2.6.5 Key Personnel
- 4.2.6.6 Analyst View
- 4.2.7 NMD Pharma A/S
- 4.2.7.1 Overview
- 4.2.7.2 Top Products/Product Portfolio
- 4.2.7.3 Top Competitors
- 4.2.7.4 Target Customers
- 4.2.7.5 Key Personnel
- 4.2.7.6 Analyst View
- 4.2.8 Bausch Health Companies Inc.
- 4.2.8.1 Overview
- 4.2.8.2 Top Products/Product Portfolio
- 4.2.8.3 Top Competitors
- 4.2.8.4 Target Customers
- 4.2.8.5 Key Personnel
- 4.2.8.6 Analyst View
- 4.2.9 Amgen Inc.
- 4.2.9.1 Overview
- 4.2.9.2 Top Products/Product Portfolio
- 4.2.9.3 Top Competitors
- 4.2.9.4 Target Customers
- 4.2.9.5 Key Personnel
- 4.2.9.6 Analyst View
- 4.2.10 Teva Pharmaceutical Industries Ltd.
- 4.2.10.1 Overview
- 4.2.10.2 Top Products/Product Portfolio
- 4.2.10.3 Top Competitors
- 4.2.10.4 Target Customers
- 4.2.10.5 Key Personnel
- 4.2.10.6 Analyst View
- 4.2.11 Merck and Co., Inc.
- 4.2.11.1 Overview
- 4.2.11.2 Top Products/Product Portfolio
- 4.2.11.3 Top Competitors
- 4.2.11.4 Target Customers
- 4.2.11.5 Key Personnel
- 4.2.11.6 Analyst View
- 5. Research Methodology
- List of Figures
- Figure: Global Myasthenia Gravis Market Coverage
- Figure: Global Myasthenia Gravis Market Key Trends, Impact Analysis, 2024-2035
- List of Tables
- Table: Global Myasthenia Gravis Market (by Drug Class), $Million, 2024-2035
- Table: Global Myasthenia Gravis Market (by Region), $Million, 2024-2035
- Table: Global Myasthenia Gravis Market, Dynamics Impact Analysis
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook